Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/01/21
End: 03/30/26
Due: 03/30/27
Phase: N/A
Priority: Normal
Start: 04/01/21
End: 03/30/26
Due: 03/30/27
Phase: N/A
Priority: Normal
Start: 04/01/21
End: 03/30/26
Due: 03/30/27
Phase: N/A
Priority: Normal
Start: 10/24/23
End: 07/31/28
Due: 07/31/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis | NCT04943198 | Anna Raciborska | user2@example.com | None | 2021-04-01 | 2026-03-30 | 2027-03-30 | - | - | 2025-07-14 |
| Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging | NCT04943211 | Anna Raciborska | user2@example.com | None | 2021-04-01 | 2026-03-30 | 2027-03-30 | - | - | 2025-07-14 |
| Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients | NCT04943224 | Anna Raciborska | user2@example.com | None | 2021-04-01 | 2026-03-30 | 2027-03-30 | - | - | 2025-07-14 |
| To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) | NCT05968768 | Anna Raciborska | user2@example.com | None | 2023-10-24 | 2028-07-31 | 2029-07-31 | - | - | 2025-07-14 |